A solid tumor gene profiling test by next-generation sequencing was conducted by the FoundationOne CDx assay, which showed that the tumor had a low tumor mutational burden (TMB) of 5 mutants per megabase (muts/mb), positive PI3KCA mutation (p. H1047R), and MYCN amplification. This evidence concerns the gene MYCN and neoplasm.